Innate Pharma SA
PAR:IPH
Innate Pharma SA
Other
Innate Pharma SA
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Innate Pharma SA
PAR:IPH
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Valneva SE
PAR:VLA
|
Other
-€18.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
G
|
Genfit SA
PAR:GNFT
|
Other
-€260k
|
CAGR 3-Years
60%
|
CAGR 5-Years
47%
|
CAGR 10-Years
-7%
|
|
Inventiva SA
PAR:IVA
|
Other
€5.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Eurobio Scientific SA
PAR:ALERS
|
Other
-€2.3m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
||
OSE Immunotherapeutics SA
PAR:OSE
|
Other
€538k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
79%
|
CAGR 10-Years
N/A
|
Innate Pharma SA
Glance View
Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. The company is headquartered in Marseille, Paca and currently employs 215 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The firm works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.